Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12
| Författare |
Edith Schneider Anna Staffas Linda Röhner Kathrin Krowiorz Michael Heuser Konstanze Döhner Lars Bullinger Hartmut Döhner Linda Fogelstrand Arefeh Rouhi Florian Kuchenbauer Lars Palmqvist |
|---|---|
| Publicerad i | Experimental hematology |
| Volym | 44 |
| Nummer/häfte | 12 |
| Sidor | 1166-71 |
| ISSN | 1873-2399 |
| Publiceringsår | 2016 |
| Publicerad vid |
Institutionen för biomedicin, avdelningen för klinisk kemi och transfusionsmedicin |
| Sidor | 1166-71 |
| Språk | en |
| Länkar |
dx.doi.org/10.1016/j.exphem.2016.08... |
| Ämnesord | AML, MLL, miRNA |
| Ämneskategorier | Molekylär medicin (genetik och patologi), Molekylärbiologi, Hematologi |
MicroRNA-155 (miR-155) is an oncogenic miRNA upregulated in various tumor types and leukemias and has been suggested as a potential drug target. Based on our previous work detecting high miR-155 levels in response to Meis1 overexpression in a murine Hox leukemia model, we show here the relationship among HOXA9, MEIS1, and miR-155 levels in MLL-translocated acute myeloid leukemia (AML) patients. Using mouse bone marrow cells transformed by MLL-fusion genes expressing graduated levels of Meis1, we show a positive correlation between miR-155 and Meis1. However, using a miR-155-knockout mouse model, we show that the absence and the depletion of miR-155 have no effect on leukemia formation or progression. We also show for the first time that miR-155 levels are correlated with MLL translocations, but that miR-155 expression is dispensable for the formation of AML and has no effect on leukemia progression.
GÖTEBORGS UNIVERSITET • Box 100 • 405 30 Göteborg • Telefon: 031 786 0000
Kontakt • Organisationsnummer: 202100-3153 • Om webbplatsen
Facebook
Twitter
Instagram
Snapchat
Youtube